343 related articles for article (PubMed ID: 10688619)
21. Metabolism of phencyclidine by human liver microsomes.
Laurenzana EM; Owens SM
Drug Metab Dispos; 1997 May; 25(5):557-63. PubMed ID: 9152594
[TBL] [Abstract][Full Text] [Related]
22. Age-related changes in the protein and mRNA levels of CYP2E1 and CYP3A isoforms as well as in their hepatic activities in Wistar rats. What role for oxidative stress?
Wauthier V; Verbeeck RK; Buc Calderon P
Arch Toxicol; 2004 Mar; 78(3):131-8. PubMed ID: 14600803
[TBL] [Abstract][Full Text] [Related]
23. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists.
Martínez C; Albet C; Agúndez JA; Herrero E; Carrillo JA; Márquez M; Benítez J; Ortiz JA
Clin Pharmacol Ther; 1999 Apr; 65(4):369-76. PubMed ID: 10223772
[TBL] [Abstract][Full Text] [Related]
24. Cytochrome P450 Involvement in the biotransformation of cisapride and racemic norcisapride in vitro: differential activity of individual human CYP3A isoforms.
Pearce RE; Gotschall RR; Kearns GL; Leeder JS
Drug Metab Dispos; 2001 Dec; 29(12):1548-54. PubMed ID: 11717173
[TBL] [Abstract][Full Text] [Related]
25. Ethanol inhibits in-vitro metabolism of nifedipine, triazolam and testosterone in human liver microsomes.
Patki KC; Greenblatt DJ; von Moltke LL
J Pharm Pharmacol; 2004 Aug; 56(8):963-6. PubMed ID: 15285839
[TBL] [Abstract][Full Text] [Related]
26. Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole.
Chien JY; Lucksiri A; Ernest CS; Gorski JC; Wrighton SA; Hall SD
Drug Metab Dispos; 2006 Jul; 34(7):1208-19. PubMed ID: 16611859
[TBL] [Abstract][Full Text] [Related]
27. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping.
Lee JI; Chaves-Gnecco D; Amico JA; Kroboth PD; Wilson JW; Frye RF
Clin Pharmacol Ther; 2002 Dec; 72(6):718-28. PubMed ID: 12496753
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetic interaction of cytochrome P450 3A-related compounds with rhodamine 123, a P-glycoprotein substrate, in rats pretreated with dexamethasone.
Yumoto R; Murakami T; Sanemasa M; Nasu R; Nagai J; Takano M
Drug Metab Dispos; 2001 Feb; 29(2):145-51. PubMed ID: 11159804
[TBL] [Abstract][Full Text] [Related]
29. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
Kharasch ED; Walker A; Hoffer C; Sheffels P
Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
[TBL] [Abstract][Full Text] [Related]
30. Age-related differences in CYP3A expression and activity in the rat liver, intestine, and kidney.
Warrington JS; Greenblatt DJ; von Moltke LL
J Pharmacol Exp Ther; 2004 May; 309(2):720-9. PubMed ID: 14742746
[TBL] [Abstract][Full Text] [Related]
31. Effect of oral ketoconazole on intestinal first-pass effect of midazolam and fexofenadine in cynomolgus monkeys.
Ogasawara A; Kume T; Kazama E
Drug Metab Dispos; 2007 Mar; 35(3):410-8. PubMed ID: 17142564
[TBL] [Abstract][Full Text] [Related]
32. Small intestinal metabolism of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor lovastatin and comparison with pravastatin.
Jacobsen W; Kirchner G; Hallensleben K; Mancinelli L; Deters M; Hackbarth I; Baner K; Benet LZ; Sewing KF; Christians U
J Pharmacol Exp Ther; 1999 Oct; 291(1):131-9. PubMed ID: 10490896
[TBL] [Abstract][Full Text] [Related]
33. Lack of correlation between in vitro and in vivo studies on the effects of tangeretin and tangerine juice on midazolam hydroxylation.
Backman JT; Mäenpää J; Belle DJ; Wrighton SA; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 2000 Apr; 67(4):382-90. PubMed ID: 10801247
[TBL] [Abstract][Full Text] [Related]
34. In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: role of cytochrome P450 3A.
Quintieri L; Rosato A; Napoli E; Sola F; Geroni C; Floreani M; Zanovello P
Cancer Res; 2000 Jun; 60(12):3232-8. PubMed ID: 10866316
[TBL] [Abstract][Full Text] [Related]
35. Activity of CYP2E1 and CYP3A enzymes in adults with moderate alcohol consumption: a comparison with nonalcoholics.
Liangpunsakul S; Kolwankar D; Pinto A; Gorski JC; Hall SD; Chalasani N
Hepatology; 2005 May; 41(5):1144-50. PubMed ID: 15841467
[TBL] [Abstract][Full Text] [Related]
36. Microsomal metabolism of delavirdine: evidence for mechanism-based inactivation of human cytochrome P450 3A.
Voorman RL; Maio SM; Payne NA; Zhao Z; Koeplinger KA; Wang X
J Pharmacol Exp Ther; 1998 Oct; 287(1):381-8. PubMed ID: 9765359
[TBL] [Abstract][Full Text] [Related]
37. N-Dealkylation and hydroxylation of ebastine by human liver cytochrome P450.
Hashizume T; Mise M; Terauchi Y; O L; Fujii T; Miyazaki H; Inaba T
Drug Metab Dispos; 1998 Jun; 26(6):566-71. PubMed ID: 9616193
[TBL] [Abstract][Full Text] [Related]
38. Interaction of diclofenac and quinidine in monkeys: stimulation of diclofenac metabolism.
Tang W; Stearns RA; Kwei GY; Iliff SA; Miller RR; Egan MA; Yu NX; Dean DC; Kumar S; Shou M; Lin JH; Baillie TA
J Pharmacol Exp Ther; 1999 Dec; 291(3):1068-74. PubMed ID: 10565826
[TBL] [Abstract][Full Text] [Related]
39. Cytochrome P4502B6 and 2C9 do not metabolize midazolam: kinetic analysis and inhibition study with monoclonal antibodies.
Hamaoka N; Oda Y; Hase I; Asada A
Br J Anaesth; 2001 Apr; 86(4):540-4. PubMed ID: 11573629
[TBL] [Abstract][Full Text] [Related]
40. Human liver microsomal reduction of pyrrolizidine alkaloid N-oxides to form the corresponding carcinogenic parent alkaloid.
Wang YP; Yan J; Fu PP; Chou MW
Toxicol Lett; 2005 Mar; 155(3):411-20. PubMed ID: 15649625
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
